Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HB-101 Vaccine in Healthy Volunteers
NCT02798692Phase 1Completed
- Sponsor
- HOOKIPA Pharma
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB-101 in cytomegalovirus infection (CMV) (4 arms), sponsored by HOOKIPA Pharma. Primary endpoints: Safety primary outcome (local solicited symptoms), Safety primary outcome (general solicited symptoms) and 5 more. Started Jun 2016; status: completed.
02
Drugs
HB-101
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02798692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798692.